BioSpace News Archive

Amid accelerated demand for its dental artificial intelligence software, Overjet announced it has raised $42.5 million in Series B financing led by General Catalyst and Insight Partners with participation from existing investors Crosslink Capital and the MIT-affiliated E14 Fund in an oversubscribed round.

Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer’s Disease is not very well established, particularly given the multiplicity of bio factors implicated in this devastating disease.

In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph should be Wednesday, Jan. 12, 2022 at 1:30 p.m. EST instead of Wednesday, Jan. 12, 2021 at 1:30 p.m. EST.

Texas Biomedical Research Institute’s inaugural bond sale has been named the 2021 Deal of the Year by Smith’s Research and Gradings, an investment research and analysis company.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.

Avra, Inc. (OTC PINK: AVRN), is pleased to announce that it has closed the merger with Springs Rejuvenation, LLC (https://springsrejuvenation.com).

Novavax, Inc. announced that the World Health Organization has granted a second Emergency Use Listing for NVX-CoV2373, Novavax’ recombinant protein nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Orphan drugs are novel drugs which are dedicated to treat the disease conditions that are rare as well as life-threatening to small percentage of patient population at global level.

Opiant Pharmaceuticals, Inc. announced the Compensation Committee of the Company’s Board of Directors has approved the grant of restricted stock units covering an aggregate of 31,500 shares of common stock to six hired employees, pursuant to the Company’s 2021 Inducement Equity Incentive Plan.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (ADP). Resubmission of the sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022.